Articles by Lung Cancers Today Editors
Rilertinib showed significantly longer progression-free survival compared with gefitinib.
Plinabulin combined with docetaxel showed improved survival in patients with wild-type EGFR NSCLC.
Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in NSCLC.
Osimertinib demonstrated a manageable safety profile for the treatment of stage III EGFR-mutated NSCLC.
More than one-third of patients with platinum-resistant ES-SCLC responded to treatment.
A personalized music therapy regimen also mediated postoperative dyspnea symptoms.
HR20013 was noninferior to fosaprepitant plus palonesetron at reducing nausea related to cisplatin-based chemotherapy.
Nivolumab with or without relatlimab demonstrated promising survival rates at 2 years postoperatively.
Novocure will examine TTFields at the conference, placing particular emphasis on a post-hoc analysis using data from LUNAR.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.